{ }
001122334455554433221100
001122334455554433221100

Chinese biotech firms report 18 percent increase in overseas deals in Q1

Chinese biotech firms experienced an 18% increase in overseas deals in Q1 2025, completing 33 transactions worth a total of US$36.2 billion, up from 28 agreements the previous year. Notable deals included a collaboration between GeneQuantum, Biohaven, and AimedBio, as well as a US$4.7 billion partnership between Harbour BioMed and AstraZeneca focused on next-generation antibodies for immunology and oncology.

Immunovant data boosts Biohaven outlook according to Deutsche Bank

Deutsche Bank has reported positive data from Immunovant for Biohaven, highlighting its potential impact on the market. This development is seen as significant in the financial landscape, reflecting optimism around Biohaven's prospects.

setbacks in drug development impact schizophrenia and oncology markets

AbbVie's schizophrenia drug emraclidine failed two mid-phase trials, performing no better than placebo, resulting in a $40 billion market cap loss for the company. This setback follows the recent approval of Bristol Myers Squibb's Cobenfy, the first new schizophrenia drug in decades, which boosted BMS's share price by 12%. The failure raises concerns for other companies developing similar drugs in the same class.

averill partners closes to new investors after impressive fund performance

Averill Partners, a biopharma-focused long-short hedge fund, will stop accepting new investments starting November 1, having achieved a remarkable 385.8% return since its launch in early 2020. The fund, led by Kishen Mehta, has excelled through strategic short selling and currently manages $1.7 billion in assets. Averill Madison, a separate health care fund, remains open to new capital.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.